节点文献
痰热清治疗慢性阻塞性肺疾病急性加重期的临床疗效及细胞因子水平的研究
Study of clinical effect on treatment of chronic obstructive pulmonary disease in acute aggravated stage with tanreqing injection and cell factor level
【摘要】 目的:探讨痰热清注射液治疗慢性阻塞性肺疾病(COPD)急性加重期的临床疗效及细胞因子水平的变化。方法:选择87例COPD急性加重期患者,随机分为两组,治疗组44例用痰热清注射液20mL加入5%葡萄糖生理盐水500mL中静脉滴注,每日1次。对照组炎琥宁注射液0.4g加入5%葡萄糖生理盐水250m静脉滴注,每日1次,2组疗程均为2周。分别于治疗前后观察临床疗效和TL-10,TNF-α,MPO的变化。结果:治疗组总有效率94.31%,对照组总有效率83.75%。差异有显著性(P<0.01)。两组IL-10水平均较健康组低(P<0.01)。而TNF-α及MPO较健康组高(P<0.01)。治疗后治疗组TNF-α,MPO水平与对照组比明显降低(P<0.01),IL-10与对照组比明显增高,差异有显著性(P<0.01)。结论:痰热清治疗COPD急性加重期效果显著,无明显毒性作用,临床使用安全。且能有效地抑制上述细胞因子的释放,是治疗COPD急性加重期的重要作用之一。
【Abstract】 Objective:To make a study of the clinical effect on the treatment of chronic obstructive pulmonary disease in acute aggravated stage with Tanreqing Injection and the changes of the cell factor level. Method:Eighty-seven cases of COPD patients in acute aggravated stage were chosen and divided into two groups at random. Forty-four cases in treatment group were given intravenous drip of Tanreqing(20 mL) with 5% G/NS(500 mL) once a day. Forty-three cases in control group were given intravenous drip Yanhuning injection(0.4 g) with 5% G/NS(500 mL) once a day. The courses of the treatment were both two weeks and the changes of TL-10,TNF-α and MPO were observed separately before and after the treatment. Result:The total effective rate in the treatment group was 94.31% while the control group 83.75%,which had significant difference(P<0.05) . IL-10 level in both groups was comparatively lower than the healthy(P<0.01) ,while TNF-α and MPO was higher than the healthy(P<0.01) . After the treatment,the TNF-αand MPO level in the treatment group decreased more greatly than those in the control group(sP<0.01) but the IL-10 increased a lot more than those in the control group and there existed remarkable difference(P<0.01) . Conclusion:The treatment of chronic obstructive pulmonary disease in acute aggravated stage with Tanreqing Injection can have noticeable effect,and can prohibit the release of above cell factors. It is also safe in clinical use without obvious side effects and has played an important role in the treatment of chronic obstructive pulmonary disease in acute aggravated stage.
- 【文献出处】 中国中药杂志 ,China Journal of Chinese Materia Medica , 编辑部邮箱 ,2009年01期
- 【分类号】R259
- 【被引频次】40
- 【下载频次】396